ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) — Bionomics Limited BNOXBNO)) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators that promise to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical needs, today announced its participation the following upcoming investor conferences in November:
- Credit Suisse 31St Annual health conference
- Evercore ISI 5th Annual HealthCONx Conference
- Fireside chat: November 29th at 9:15 p.m. ET
An audio webcast link for select events, when available, will be posted on the Events and Presentations page of the Investors section of Bionomics’ website.
Dismissed by authorization of the Executive Chairman.
FOR MORE INFORMATION PLEASE CONTACT:
About Bionomics Limited
bionomics (BNOBNOX is a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators that promise to transform the lives of patients suffering from severe CNS disorders with high unmet medical needs. Bionomics is developing its lead drug candidate BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD). In addition to BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the US and Canada) with two drugs in early clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system disorders.
[ad_2]
Source story
